Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? - Wikidata - awgldk - TriplyDB

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

http://www.wikidata.org/entity/Q36936900

about

Geraniol Suppresses Angiogenesis by Downregulating Vascular Endothelial Growth Factor (VEGF)/VEGFR-2 Signaling Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer.The -1154 G/A VEGF gene polymorphism is associated with the incidence of basal cell carcinoma in patients from northern Poland.Ziv-aflibercept in metastatic colorectal cancer Establishment of genetically diverse patient-derived xenografts of colorectal cancer.A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial.MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.Endothelial progenitor cells in tumor angiogenesis: another brick in the wall.Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice.The Dual Role of MicroRNAs in Colorectal Cancer Progression

P2860

Q28546382-350C08B0-530B-4BBB-8D57-02D6D8F5097E Q33800676-2C9487B6-D149-4984-ACDD-A6D888C5BF81 Q33935434-CF853F8C-1C85-4DBD-A439-80D40E53D58B Q34658579-84B36DF9-5F7E-4E81-B437-A5FC2078588D Q34704942-F35C639C-993E-4FB0-A70C-1C6D5FE58F25 Q35604265-39FE81DA-1302-4525-AD58-B77578D0EC7D Q38241985-1059A083-61AB-4DC0-91C3-A40A3FB638EB Q38247982-A990B16D-85EA-4D30-9738-543E6E781759 Q38497288-1B4BD557-FBFE-4F57-AF4B-FEAE8D110ED7 Q38711732-955D7363-6635-46F0-89EE-C81DB04825AC Q58729731-CF8B3B38-3F6E-4CFA-B590-C28406455B9D

P2860

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

http://www.wikidata.org/entity/Q36936900

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

@en

type

label

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

@en

prefLabel

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

@en

P1433

Q36936900-CE50AE1F-7787-41B9-8A35-F40043A1AEDE

P1476

Q36936900-5F9E658B-3E40-4BFA-97A8-D28C83D9CB86

P2093

Q36936900-9C9DFA35-1EC4-43DA-9D00-5299B274F0CC

P2860

Q36936900-070595AA-B1C9-4E10-8D43-5237E7E49B28

Q36936900-0766A8F4-11D8-4F99-A806-F0062318C760

Q36936900-0F077A5D-786E-495B-805E-24DA699998A7

Q36936900-0F8B9EFF-D96D-4650-A7B9-1CCDA75A8F7D

Q36936900-0F96345A-AF65-45A7-A132-7CAEDE2D0CF0

Q36936900-10E5F6C4-E15C-4142-854C-E527054EF233

Q36936900-12460D67-F235-4234-895F-A1261E48A493

Q36936900-14B2DF1E-78E7-4B98-BD35-6E018C07DC08

Q36936900-15C56DD4-FC69-4C07-8340-379AD2CDEB06

Q36936900-1800825D-666C-4A5A-8E4D-91A700867637

P304

Q36936900-B3AEC51D-2D17-4CDF-9710-19FBE0F3D376

P31

Q36936900-46ECC4FF-77B4-4CCA-83D8-BC69357B71EB

P356

Q36936900-90C95F95-DFAA-4643-8470-6274B1DA826F

P407

Q36936900-B9839EFA-E9B1-4323-8019-AE738D8633D6

P478

Q36936900-29A59620-3C5C-44A8-9306-59ECC93BCB5D

P577

Q36936900-92347ADE-55B2-489F-B812-0ED1542B5339

P5875

Q36936900-EACFD43E-DB5B-43E3-9D81-F5545E0D08CC

P698

Q36936900-4C73857F-DA68-4265-BF92-A20FF78A2070

P921

Q36936900-B339764C-6FD6-4B80-8D31-86E6E5E9841E

P932

Q36936900-FD9D4FE7-4157-4B6F-9E8E-22442BC9EC48

P356

P1433

Cancer Management and Research

P1476

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

@en

P2093

Muhammad Wasif Saif

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform

VEGF-Trap: a VEGF blocker with potent antitumor effects.

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Molecular mechanisms and clinical applications of angiogenesis

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Angiogenic factors

P304

103-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S45193

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

242653625

http://www.w3.org/2001/XMLSchema#string

P698

23807861

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3685399

http://www.w3.org/2001/XMLSchema#string